Scancell points to 'strong' melanoma vaccine data Scancell has the results it was hoping for with its melanoma immunotherapy iSCIB1+ and is accelerating plans for a pivotal trial.

#Scancell #NationalCancerInstitute #UKbiotech #DNAplasmidvaccine #melanoma #SCOPEtrial #SCIB1 #iSCIB1+ #checkpointinhibitortherapy #advancedmelanoma #immunotherapy #melanomaantigens #TRP2protein #Tcells #checkpointinhibitors #metastaticmelanomatreatment
pharmaphorum.com/news/scancel...